These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 37242462)

  • 1. Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients.
    Tseng CH
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus.
    Tseng CH
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36558989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis.
    Tseng CH
    BMC Cancer; 2022 May; 22(1):559. PubMed ID: 35585577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin Use Is Associated with a Lower Risk of Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus.
    Tseng CH
    J Crohns Colitis; 2021 Jan; 15(1):64-73. PubMed ID: 32604412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients.
    Tseng CH
    Aging (Albany NY); 2019 May; 11(9):2724-2734. PubMed ID: 31085804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Analysis.
    Tseng CH
    J Clin Med; 2018 Sep; 7(10):. PubMed ID: 30262775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin use is associated with a reduced risk of acute appendicitis in Taiwanese patients with type 2 diabetes mellitus.
    Tseng CH
    Sci Rep; 2021 Jun; 11(1):12400. PubMed ID: 34117321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin and risk of gingival/periodontal diseases in diabetes patients: A retrospective cohort study.
    Tseng CH
    Front Endocrinol (Lausanne); 2022; 13():1036885. PubMed ID: 36277720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Risk of Age-Related Macular Degeneration Is Reduced in Type 2 Diabetes Patients Who Use Metformin.
    Tseng CH
    Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37259372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic Metformin Therapy is Associated with a Lower Risk of Hemorrhoid in Patients with Type 2 Diabetes Mellitus.
    Tseng CH
    Front Pharmacol; 2020; 11():578831. PubMed ID: 33664665
    [No Abstract]   [Full Text] [Related]  

  • 11. Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus.
    Tseng CH
    Oncotarget; 2017 Jan; 8(2):3042-3048. PubMed ID: 27936468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus.
    Tseng CH
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin Use Is Associated With a Lower Incidence of Hospitalization for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus.
    Tseng CH
    Front Med (Lausanne); 2020; 7():592901. PubMed ID: 33693008
    [No Abstract]   [Full Text] [Related]  

  • 14. Metformin Is Associated with a Lower Incidence of Benign Brain Tumors: A Retrospective Cohort Study in Patients with Type 2 Diabetes Mellitus.
    Tseng CH
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680039
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of Metformin on Lower Urinary Tract Symptoms in Male Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study in Taiwan.
    Tseng CH
    World J Mens Health; 2023 Jul; 41(3):680-691. PubMed ID: 36593711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.
    Tseng CH
    Front Endocrinol (Lausanne); 2023; 14():1185053. PubMed ID: 37560306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study.
    Tseng CH
    Int J Chron Obstruct Pulmon Dis; 2022; 17():285-295. PubMed ID: 35177899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients.
    Tseng CH
    Front Endocrinol (Lausanne); 2021; 12():637392. PubMed ID: 33995274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan.
    Tseng CH
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
    Tseng CH
    Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.